letrozole has been researched along with sirolimus in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (40.74) | 29.6817 |
| 2010's | 15 (55.56) | 24.3611 |
| 2020's | 1 (3.70) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Ellis, M | 1 |
| Boulay, A; Chen, S; Evans, DB; Lane, HA; O'Reilly, T; Rudloff, J; Ye, J; Zumstein-Mecker, S | 1 |
| Lane, HA; Lebwohl, D | 1 |
| Abrial, C; Chollet, P; Curé, H; Durando, X; Leheurteur, M; Mouret-Reynier, MA; Tacca, O | 1 |
| Beeram, M; DeGraffenried, LA; Middleton, A; Russell, D; Tan, QT; Tekmal, RR | 1 |
| Awada, A; Cardoso, F; De Grève, J; Dirix, L; Fontaine, C; Piccart, M; Sotiriou, C; Steinseifer, J; Tanaka, C; Tang, P; Wouters, C; Zoellner, U | 1 |
| Collingridge, D | 1 |
| Fricker, J | 1 |
| Baselga, J; Bellet, M; Bianchi, G; Campone, M; Dixon, JM; Gardner, H; Greil, R; Jonat, W; Kubista, E; Lane, HA; Manikhas, A; Mayordomo, J; Molloy, B; Phillips, P; Rugo, HS; Semiglazov, V; Steinseifer, J; Stumm, M; Tokaji, E; van Dam, P | 1 |
| Ancochea, J; Casanova, A | 1 |
| de Azambuja, E; Metzger-Filho, O | 1 |
| Airoud, K; Alfieri, RR; Andreis, D; Bertoni, R; Bonelli, MA; Bottini, A; Cavazzoni, A; Fumarola, C; Galetti, M; Galvani, E; Generali, D; Harris, AL; La Monica, S; Martin, LA; Petronini, PG; Tramonti, S | 1 |
| Ito, Y | 1 |
| A'Hern, R; Dowsett, M; Evans, DB; Farmer, I; Ghazoui, Z; Guest, S; Johnston, SR; Lane, HA; Martin, LA; Pancholi, S; Ribas, R; Thornhill, AM; Weigel, MT | 1 |
| De, G; Diener, M; Namjoshi, M; Wu, EQ; Xie, J; Yang, H | 1 |
| Berkenblit, A; Bondarenko, I; Brincat, S; Chan, A; Chow, L; Cincotta, M; Fumoleau, P; Garin, AM; Guimaraes, RC; Hachemi, S; Hayes, DF; Kang, LL; Krygowski, M; Lazar, AA; Moore, L; Neskovic-Konstantinovic, Z; Strahs, A; Sun, Y; Wolff, AC | 1 |
| Bartlett, JM; Baselga, J; Dixon, JM; Loi, S; Michiels, S; Piccart, MJ; Sabine, VS; Sahmoud, T; Sims, AH; Singhal, SK; Sotiriou, C | 1 |
| Hou, G; Liu, J; Liu, Y; Zhang, J; Zhang, S; Zhang, X | 1 |
| Mehta, A; Tripathy, D | 1 |
| Lu, XY; Xu, H; Yang, Y; Zeng, T; Zhang, ZZ | 1 |
| Brown, MP; Singhal, N; Vatandoust, S | 1 |
| Coleman, RL; Gershenson, DM; Jiang, Y; Johnston, T; Levenback, C; Lu, KH; Munsell, MF; Nowakowski, M; Ring, K; Slomovitz, BM; Soliman, PT; Yates, MS; Zhang, Q | 1 |
| Chavez-MacGregor, M; Duan, Z; Giordano, SH; Sharma, M; Zhao, H | 1 |
5 review(s) available for letrozole and sirolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Overcoming endocrine therapy resistance by signal transduction inhibition.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Farnesyltranstransferase; Humans; Immunosuppressive Agents; Letrozole; Nitriles; Receptor, ErbB-2; Receptors, Estrogen; Sirolimus; Tamoxifen; Triazoles | 2004 |
Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
Topics: Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Everolimus; Female; Forecasting; Humans; Immunosuppressive Agents; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Sirolimus; Triazoles | 2006 |
[Progress of molecularly targeted therapy for breast cancer].
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Denosumab; Drug Design; Drug Therapy, Combination; Everolimus; Humans; Lapatinib; Letrozole; Maytansine; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Sirolimus; Tamoxifen; Trastuzumab; Triazoles | 2012 |
Co-targeting estrogen receptor and HER2 pathways in breast cancer.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; Trastuzumab; Triazoles | 2014 |
6 trial(s) available for letrozole and sirolimus
| Article | Year |
|---|---|
The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Drug Interactions; Everolimus; Feasibility Studies; Female; Humans; Immunosuppressive Agents; Letrozole; Male; Middle Aged; Nitriles; Sirolimus; Treatment Outcome; Triazoles | 2008 |
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Cell Proliferation; Chemotherapy, Adjuvant; Class I Phosphatidylinositol 3-Kinases; Cyclin D1; Double-Blind Method; Europe; Everolimus; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Letrozole; Middle Aged; Mutation; Neoadjuvant Therapy; Nitriles; Palpation; Phosphatidylinositol 3-Kinases; Phosphorylation; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Ribosomal Protein S6 Kinases; Sirolimus; Time Factors; Treatment Outcome; Triazoles; United States | 2009 |
Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Placebos; Postmenopause; Sirolimus; Treatment Outcome; Triazoles | 2013 |
PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Everolimus; Female; Gene Expression Regulation, Neoplastic; Genotype; Humans; Letrozole; Middle Aged; Mutation; Nitriles; Phosphatidylinositol 3-Kinases; Receptors, Estrogen; Sirolimus; TOR Serine-Threonine Kinases; Triazoles | 2013 |
Phase II study evaluating efficacy and safety of everolimus with letrozole for management of advanced (unresectable or metastatic) non-small cell lung cancer after failure of platinum-based treatment: a preliminary analysis of toxicity.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Carcinoma, Non-Small-Cell Lung; Everolimus; Female; Humans; Letrozole; Lung Diseases; Lung Neoplasms; Male; Middle Aged; Nitriles; Organoplatinum Compounds; Sirolimus; Smoking; Triazoles | 2015 |
Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bayes Theorem; beta Catenin; Biomarkers, Tumor; Cohort Studies; Disease-Free Survival; DNA Mutational Analysis; Endometrial Neoplasms; Endometriosis; Everolimus; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Immunosuppressive Agents; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Phosphoinositide-3 Kinase Inhibitors; Receptors, Estrogen; Receptors, Progesterone; Sirolimus; Time Factors; TOR Serine-Threonine Kinases; Treatment Outcome; Triazoles | 2015 |
16 other study(ies) available for letrozole and sirolimus
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma; Cell Proliferation; Cell Survival; Drug Interactions; Estrogens; Everolimus; Female; Humans; Immunosuppressive Agents; Letrozole; Nitriles; Protein Kinases; Receptors, Estrogen; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Triazoles; Tumor Cells, Cultured | 2005 |
Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Letrozole; Nitriles; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein Kinases; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome; Triazoles | 2006 |
Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Everolimus; Female; Flow Cytometry; Fulvestrant; Humans; Letrozole; Nitriles; Protein Kinases; Proto-Oncogene Proteins c-akt; Sirolimus; TOR Serine-Threonine Kinases; Triazoles | 2007 |
San Antonio Breast Cancer Symposium.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Epothilones; Everolimus; Female; Fluorouracil; Humans; Letrozole; Nitriles; Sirolimus; Tamoxifen; Taxoids; Trastuzumab; Triazoles | 2008 |
San Antonio Breast Cancer Symposium.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Diphosphonates; Everolimus; Female; Humans; Imidazoles; Lapatinib; Letrozole; Nitriles; Quinazolines; Sirolimus; Tamoxifen; Trastuzumab; Triazoles; Zoledronic Acid | 2009 |
[Lymphangioleiomyomatosis: new therapeutic approaches].
Topics: Adult; Aromatase Inhibitors; Clinical Trials, Phase II as Topic; Doxycycline; Estrogen Receptor Modulators; Female; Humans; Letrozole; Lung Neoplasms; Lung Transplantation; Lymphangioleiomyomatosis; Matrix Metalloproteinase Inhibitors; Multicenter Studies as Topic; Nitriles; Randomized Controlled Trials as Topic; Registries; Sirolimus; Spain; Therapies, Investigational; Triazoles | 2011 |
Neoadjuvant chemotherapy and targeted therapies: a promising strategy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; DNA Repair; Drug Discovery; Everolimus; Female; Genetic Predisposition to Disease; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Neoadjuvant Therapy; Nitriles; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Sirolimus; Trastuzumab; Triazoles | 2011 |
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones.
Topics: Aged; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Imidazoles; Immunosuppressive Agents; Letrozole; Neoadjuvant Therapy; Nitriles; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Triazoles | 2012 |
Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Nucleolus; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Letrozole; Mechanistic Target of Rapamycin Complex 1; Mice; Multiprotein Complexes; Nitriles; Phosphorylation; Protein Kinase Inhibitors; Protein Transport; Proto-Oncogene Proteins c-akt; Receptor, ErbB-3; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; TOR Serine-Threonine Kinases; Triazoles; Xenograft Model Antitumor Assays | 2012 |
Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States.
Topics: Anastrozole; Antineoplastic Agents; Breast Neoplasms; Budgets; Cost-Benefit Analysis; Drug Costs; ErbB Receptors; Everolimus; Female; Health Care Costs; Humans; Letrozole; Middle Aged; Nitriles; Receptor, ErbB-2; Severity of Illness Index; Sirolimus; Treatment Failure; Triazoles; United States | 2013 |
Everolimus in combination with letrozole inhibit human breast cancer MCF-7/Aro stem cells via PI3K/mTOR pathway: an experimental study.
Topics: Animals; Apoptosis; Aromatase; Breast Neoplasms; Cell Proliferation; Drug Synergism; Elafin; Everolimus; Female; Gene Expression Regulation, Neoplastic; Humans; Letrozole; MCF-7 Cells; Mice; Nitriles; Proto-Oncogene Proteins c-akt; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Triazoles; Xenograft Model Antitumor Assays | 2014 |
Synergistic in vitro anti-tumor effect of letrozole and everolimus on human endometrial carcinoma Ishikawa cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Endometrial Neoplasms; Everolimus; Female; Humans; Letrozole; Nitriles; Phosphatidylinositol 3-Kinases; Phosphoproteins; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Sirolimus; TOR Serine-Threonine Kinases; Triazoles | 2014 |
Real-World Patterns of Everolimus Use in Patients with Metastatic Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Humans; Letrozole; Middle Aged; Sirolimus | 2020 |